Deerfield To Go As Takeda Plans Realignment Of Post-Shire US Ops

Takeda is to close down and relocate one of its main US sites, with unspecified job losses, as it plans post-Shire restructuring, while in Japan vocal opposition to the acquisition rises.

Business reengineering
TAKEDA TO SHUT DEERFIELD SITE • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. is to close down one of its main sites in the US, relocating and rationalizing most functions, as it continues to implement restructuring around its planned $62.4bn acquisition of Shire PLC.

Activities at the Deerfield, Illinois site, which acts as the major Japanese firm's main US headquarters and currently employs nearly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By 

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

More from Scrip

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.